And they're off... Melanoma March 2016 begins!
29 February 2016
Melanoma March 2016 has kicked off with a bang! More than 300 people marched in Rockingham, WA and Devonport, TAS this weekend. It was great to see the melanoma community uniting to remember those who they have lost to melanoma, support those fighting the disease, and to raise money to support melanoma research.
Clinton Heal from MelanomaWA said of the Rockingham march “There were also many people there living with melanoma, and their family and friends were there to get behind them and the balloon release ceremony was a great way to both remember and rally together for all those touched by melanoma. With a large increase in participation compared to the 2015 event, we are excited for even bigger and better things for the 2017 Rockingham Melanoma March!”.
MIA’s Merrin Lavender attended the Devonport Melanoma March, which was the first march ever held in Tasmania. She said it was a great success and guest speakers include the founder of Melanoma TAS and the Deputy Premier of Tasmania, Jeremy Rockliff.
Thank you to everyone who came out to support Melanoma March and to our dedicated volunteers who have been tirelessly organsing these events.
This weekend marks just the beginning of a 6-week campaign for Melanoma March where Australia will unite against melanoma in 24 locations around the country. Register or make a donation to support Melanoma March today.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.